Cargando…

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of rezafungin after subcutaneous (s.c.) administ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Kenan, Ruff, Dennis, Key, Cassandra, Thompson, Marissa, Jiang, Shoshanna, Sandison, Taylor, Flanagan, Shawn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283735/ https://www.ncbi.nlm.nih.gov/pubmed/35439347 http://dx.doi.org/10.1111/cts.13286

Ejemplares similares

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

2389. Effect of Rezafungin on QT Interval in Healthy Subjects
por: Flanagan, Shawn, et al.
Publicado: (2018)

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
por: Ong, Voon, et al.
Publicado: (2020)

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
por: Rubino, Christopher M., et al.
Publicado: (2021)

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
por: Flanagan, Shawn, et al.
Publicado: (2023)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects
por: Jeon, Yoomin, et al.
Publicado: (2022)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic
por: Buda, Jeffrey J, et al.
Publicado: (2015)

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis
por: Sandison, Taylor, et al.
Publicado: (2023)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials
por: Sandison, Taylor, et al.
Publicado: (2023)

P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis
por: Soriano, A, et al.
Publicado: (2023)

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
por: Shi, Aixin, et al.
Publicado: (2020)

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336
por: Carroll, F. Ivy, et al.
Publicado: (2018)

P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
por: Thompson, G R, et al.
Publicado: (2023)

A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects
por: Leubitz, Andi, et al.
Publicado: (2021)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
por: Zhao, Yanan, et al.
Publicado: (2020)

Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins
por: Garcia-Effron, Guillermo
Publicado: (2020)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
por: Pfaller, Michael A, et al.
Publicado: (2018)

A Dose-Escalation Study Demonstrates the Safety and Tolerability of Cellobiose in Healthy Subjects
por: Moré, Margret Irmgard, et al.
Publicado: (2019)

2514. Single Ascending Dose Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza
por: Flanagan, Shawn, et al.
Publicado: (2023)

Erratum to: Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
Publicado: (2021)

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
por: Tóth, Zoltán, et al.
Publicado: (2019)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose‐escalating trial
por: Buchtele, Nina, et al.
Publicado: (2020)

Safety and Tolerability, Dose-Escalating, Double-Blind Trial of Oral Mannitol in Parkinson's Disease
por: Linetsky, Eduard, et al.
Publicado: (2022)

A randomized, double-blind, placebo controlled safety, tolerability, and pharmacokinetic dose escalation study of a gentamicin vancomycin gel in patients undergoing colorectal surgery
por: Bennett-Guerrero, Elliott, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1mubnvljje2usli3bd29sgmc4n